MicroVention's Response to COVID-19
As a leader in the global neuroendovascular industry, MicroVention-TERUMO is 100% committed to doing the right thing for our customers, associates, and patients. We have been closely following the daily developments and guidelines surrounding COVID-19, and our commitment remains true as we adjust to the current circumstances that all of us are facing during this challenging time.
Our teams are finding new ways to remain connected and to provide support virtually as we work through this together. In addition, we have implemented the following policies to ensure our associates safety and the safety our customers:
To protect the health and safety of all MicroVention-TERUMO associates, customers, and patients with utmost priority.
To maintain a stable supply of products to continuously meet global healthcare needs.
Continue to manufacture life-saving products for our patients and customers that treat real life cerebrovascular diseases, like ischemic stroke, aneurysms and arterial venous malformations.
We are in extraordinary times, but we are all in this together. MicroVention-TERUMO will continue to monitor the impact of the virus and follow protocols recommended by the CDC, government, and health officials. Furthermore, we will continue to make decisions that are guided by our core values such as “Respect, Care, and Integrity”.
Resources
Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide
Apr 22, 2020
Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO
MicroVention Expands Worldwide Innovation Center
Mar 13, 2020
Two years after MicroVention, Inc. relocated their Worldwide Innovation Center to 35 Enterprise, the neurovascular company is expanding within the Summit Office Campus to accommodate for their rapid growth.